[go: up one dir, main page]

MA27523A1 - Formulation retard a liberation controlee - Google Patents

Formulation retard a liberation controlee

Info

Publication number
MA27523A1
MA27523A1 MA28260A MA28260A MA27523A1 MA 27523 A1 MA27523 A1 MA 27523A1 MA 28260 A MA28260 A MA 28260A MA 28260 A MA28260 A MA 28260A MA 27523 A1 MA27523 A1 MA 27523A1
Authority
MA
Morocco
Prior art keywords
compositions
controlled release
release formulation
delayed controlled
polymer
Prior art date
Application number
MA28260A
Other languages
English (en)
Inventor
Guohua Chen
Paul Houston
Roy Bannister
Teresa Kameda
David Priebe
Lothar Kleiner
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32312806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27523(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of MA27523A1 publication Critical patent/MA27523A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des procédés et des compositions permettant d'administrer systématiquement ou localement un agent utile à un patient. L'invention concerne notamment des compositions de gel de dépôt qui peuvent être injectées à un emplacement souhaité et qui peuvent effectuer une administration contrôlée d'agents utiles pendant une durée prolongée. Ces compositions comprennent un polymère biocompatible, un solvant biocompatible présentant une miscibilité à l'eau faible qui forme un gel visqueux avec le polymère et qui limite l'absorption d'eau par l'implant et un agent utile.
MA28260A 2002-11-06 2005-05-05 Formulation retard a liberation controlee MA27523A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42442802P 2002-11-06 2002-11-06

Publications (1)

Publication Number Publication Date
MA27523A1 true MA27523A1 (fr) 2005-09-01

Family

ID=32312806

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28260A MA27523A1 (fr) 2002-11-06 2005-05-05 Formulation retard a liberation controlee

Country Status (25)

Country Link
US (1) US7368126B2 (fr)
EP (1) EP1581181B1 (fr)
JP (1) JP2006508127A (fr)
KR (1) KR20050088288A (fr)
CN (1) CN1713890A (fr)
AR (1) AR041913A1 (fr)
AT (1) ATE418323T1 (fr)
AU (1) AU2003295409B2 (fr)
BR (1) BR0315304A (fr)
CA (1) CA2504608C (fr)
CL (1) CL2003002277A1 (fr)
DE (1) DE60325511D1 (fr)
EC (2) ECSP055838A (fr)
MA (1) MA27523A1 (fr)
MX (1) MXPA05004927A (fr)
MY (1) MY140155A (fr)
NO (1) NO20052635L (fr)
NZ (1) NZ539810A (fr)
PE (1) PE20040675A1 (fr)
PL (1) PL377333A1 (fr)
RU (1) RU2355385C2 (fr)
TW (1) TW200503774A (fr)
UY (1) UY28067A1 (fr)
WO (1) WO2004043432A2 (fr)
ZA (1) ZA200504529B (fr)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
WO2001036000A1 (fr) * 1999-11-15 2001-05-25 Bio Syntech Canada, Inc. Solution biopolymere aqueuse auto-gelifiante en fonction du ph et a temperature controlee
US20030158302A1 (en) * 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
DE60004710T2 (de) * 1999-12-09 2004-07-08 Biosyntech Canada Inc., Laval Mineral-polymer hybrid-zusammensetzung
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
ATE320277T1 (de) * 2000-06-29 2006-04-15 Biosyntech Canada Inc Zusammensetzung und verfahren zur reparatur und regenerierung von knorpel und anderen geweben
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
AU2002221370A1 (en) * 2000-11-15 2002-05-27 Bio Syntech Canada Inc Method for restoring a damaged or degenerated intervertebral disc
EP1339438B1 (fr) * 2000-11-29 2005-10-19 Allergan Inc. Prevention du rejet de greffe dans l'oeil
MXPA04004665A (es) * 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectable y uso de los mismos.
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
BR0313539A (pt) 2002-07-31 2005-06-21 Alza Corp Composições depósito de polìmero multimodais injetáveis e seus usos
WO2004012703A1 (fr) * 2002-07-31 2004-02-12 Alza Corporation Compositions retard injectables et utilisation de ces compositions
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
CL2004000697A1 (es) * 2003-03-31 2005-05-20 Alza Corp Dispositivo de administracion osmotica que comprende: un reservorio, una composicion osmotica, la formulacion de la droga, y una membrana precargada que comprende un material semipermeable y un material liquido de relleno seleccionado de un polietile
TW200507893A (en) * 2003-03-31 2005-03-01 Alza Corp Osmotic pump with means for dissipating internal pressure
NZ542867A (en) * 2003-03-31 2009-02-28 Durect Corp Non-aqueous single phase vehicles and formulations utilizing such vehicles involving a polymer
AU2004245022A1 (en) * 2003-05-30 2004-12-16 Alza Corporation Implantable elastomeric depot compositions, uses thereof and method of manufacturing
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
WO2005107708A1 (fr) 2004-04-30 2005-11-17 Allergan, Inc. Implants d'inhibiteurs de tyrosine kinase intravitreens, biodegradables
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
WO2006078320A2 (fr) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Procede de production de systemes d'administration, et systemes d'administration
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
MX366832B (es) * 2004-10-01 2019-07-24 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
TWI369218B (en) * 2004-12-14 2012-08-01 Novartis Ag In situ forming implant for animals
EP1838285A2 (fr) * 2004-12-15 2007-10-03 QLT USA, Inc. Preparation a liberation continue de composes d'octreotide
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1871348A4 (fr) * 2005-03-01 2012-08-01 Sun Pharma Advanced Res Co Ltd Compositions pharmaceutiques a liberation prolongee
BRPI0613731A2 (pt) * 2005-07-12 2011-02-01 Renovo Ltd composição farmacêutica, recipiente enchido previamente, bem como uso de um açúcar para aprimorar a recuperação e/ou aumentar a atividade biológica de um membro da superfamìlia tgf-beta
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP1948810A4 (fr) * 2005-11-04 2010-06-30 Biosyntech Canada Inc Composition et procede utilisant du chitosan pour l'administration efficace d'acides nucleiques a des cellules
US20090048667A1 (en) * 2005-11-16 2009-02-19 Tokai University Educational System Controlled Drug-Release Composition and Drug-Releasable Medical Device
AR058591A1 (es) * 2005-12-22 2008-02-13 Novartis Ag Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-coglicolido
US8236904B2 (en) 2005-12-28 2012-08-07 Ethicon, Inc. Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates
US20070149640A1 (en) * 2005-12-28 2007-06-28 Sasa Andjelic Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
HUE030789T2 (en) 2007-05-18 2017-06-28 Durect Corp Improved depot formulation
WO2008153611A2 (fr) 2007-05-25 2008-12-18 Qlt Usa, Inc. Formulations d'administration prolongée de composés de rispéridone
WO2008149364A2 (fr) * 2007-06-07 2008-12-11 Sarah Brenner Procédés de diagnostic de réactions d'hypersensibilité
US7923021B2 (en) * 2007-07-24 2011-04-12 University Of Memphis Research Foundation Local delivery method and composition
RU2343908C1 (ru) * 2007-09-05 2009-01-20 Руслан Дмитриевич Илюк Средство для профилактики и лечения алкоголизма и способ его применения
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
CA2705520C (fr) * 2007-11-13 2016-06-28 Surmodics Pharmaceuticals, Inc. Terpolymeres visqueux en tant que plateforme de delivrance de medicaments
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
CN101917969A (zh) * 2008-01-30 2010-12-15 诺瓦提斯公司 包含奥曲肽和三种线形聚丙交酯-共-乙交酯聚合物的缓释制剂
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US7993666B2 (en) * 2008-04-18 2011-08-09 Warsaw Orthopedic, Inc. Methods and compositions for treating pain comprising a statin
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US20090263456A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
KR101760953B1 (ko) * 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. 비-수성 담체를 이용한 서방성 제형물
US9623222B2 (en) * 2008-10-30 2017-04-18 Warsaw Orthopedic, Inc. Drug depot with anchor
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
US20100158978A1 (en) * 2008-12-23 2010-06-24 Peter Markland Bioactive spray coating compositions and methods of making and uses thereof
US8951546B2 (en) 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
US9415197B2 (en) 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP2475396A4 (fr) * 2009-09-10 2013-10-16 Univ Pittsburgh Microparticules artificielles pour l'administration de macromolécules
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
RU2567792C2 (ru) 2009-11-09 2015-11-10 Аллерган, Инк. Композиции и способы стимулирования роста волос
US9993441B2 (en) 2009-12-30 2018-06-12 Surmodics, Inc. Controlled release matrix barrier structure for subcutaneous medical devices
EP3085358B1 (fr) 2010-01-22 2017-11-01 Allergan, Inc. Implants d'agent thérapeutique à libération intracamérale prolongée
WO2011133370A1 (fr) * 2010-04-23 2011-10-27 Medtronic, Inc. Dépôt pharmaceutique à longue durée de conservation
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2012030819A1 (fr) 2010-08-30 2012-03-08 Surmodics Pharmaceuticals, Inc. Terpolymères utilisés comme adhésifs sensibles à la pression
CA2810842C (fr) * 2010-09-09 2018-06-26 Micell Technologies, Inc. Formes pharmaceutiques de type macrolides
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012125914A1 (fr) * 2011-03-16 2012-09-20 University Of Delaware Système d'administration par injection de facteurs de croissance se liant à l'héparane sulfate
CN102133180B (zh) * 2011-03-18 2016-03-09 黄芳 一种甾体5α-还原酶抑制剂长效注射制剂及其制备方法
US9005634B2 (en) 2011-04-13 2015-04-14 Medtronic, Inc. Shelf stable pharmaceutical depot
ES2607497T3 (es) * 2011-04-25 2017-03-31 Shandong Luye Pharmaceutical Co., Ltd. Composición de risperidona de microesferas de liberación controlada
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
WO2013088255A1 (fr) * 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Promédicaments de composés amine secondaires
WO2013162270A1 (fr) * 2012-04-24 2013-10-31 서울대학교산학협력단 Prothèse de sein permettant la libération contrôlée de médicament et son procédé de production
US8822423B2 (en) * 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
KR20200065106A (ko) 2012-09-27 2020-06-08 알레간 인코포레이티드 단백질의 지속된 방출을 위한 생물분해성 약물 전달 시스템
CA2901280A1 (fr) 2013-02-15 2014-08-21 Allergan, Inc. Implant a administration de medicament prolongee
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
AU2014249008B2 (en) 2013-03-11 2018-12-06 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
AU2014228313B2 (en) 2013-03-15 2019-01-17 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
SG11201603383VA (en) 2013-10-31 2016-05-30 Allergan Inc Prostamide-containing intraocular implants and methods of use thereof
WO2015088990A1 (fr) 2013-12-09 2015-06-18 Durect Corporation Complexes de principes pharmaceutiquement actifs, complexes de polymères, et compositions et procédés les impliquant
WO2015101625A1 (fr) * 2013-12-31 2015-07-09 Pb&B Sa Compositions d'acides gras à libération contrôlée pour la reconstruction corporelle et le modelage corporel
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA3015557C (fr) 2014-11-07 2019-07-16 Indivior Uk Limited L'utilisation de formules de burpenorphine a liberation constante pour le traitement de la douleur ou des troubles de consommation d'opioide
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2017015675A1 (fr) 2015-07-23 2017-01-26 Envisia Therapeutics, Inc. Traitement du glaucome oculaire par l'intermédiaire d'implants intracamérulaires
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
KR20190025635A (ko) 2016-06-30 2019-03-11 듀렉트 코퍼레이션 데포 제형
CA3049034A1 (fr) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methodes comprenant l'administration continue d'un agoniste du recepteur glp-1 et la co-adminstration d'un medicament
JP7254719B2 (ja) 2017-06-13 2023-04-10 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 薬物送達用のポリマーペースト組成物
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN119185557A (zh) 2018-04-06 2024-12-27 阿玛治疗公司 用于控释治疗剂的组合物
CN109898236B (zh) * 2019-03-15 2021-12-14 深圳市光远生物材料有限责任公司 一种载药纳米纤维膜及其制备方法和应用
WO2021146215A1 (fr) 2020-01-13 2021-07-22 Durect Corporation Systèmes d'administration de médicament à libération prolongée avec impuretés réduites et procédés associés
CN111548482B (zh) * 2020-04-02 2022-09-13 复旦大学 一氧化氮供体修饰的共聚物、包含其的缓释制剂及其制备方法与应用
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法
WO2023278695A1 (fr) * 2021-06-30 2023-01-05 The University Of North Carolina At Chapel Hill Suspension de médicament à base de polymère injectable, biodégradable et amovible pour administration de médicament à action ultra-prolongée
CN116270491A (zh) * 2023-03-30 2023-06-23 北京博恩特药业有限公司 一种醋酸亮丙瑞林缓释微球及其制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797492A (en) * 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3887790A (en) * 1974-10-07 1975-06-03 Vernon H Ferguson Wrap-around electric resistance heater
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5933320B2 (ja) * 1981-04-03 1984-08-15 株式会社東芝 光学的情報記録媒体
US4443340A (en) * 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US4985404A (en) * 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5085866A (en) * 1988-12-02 1992-02-04 Southern Research Institute Method of producing zero-order controlled-released devices
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5620700A (en) * 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
GB9027422D0 (en) * 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5288214A (en) * 1991-09-30 1994-02-22 Toshio Fukuda Micropump
ES2139646T3 (es) * 1991-12-19 2000-02-16 Mitsui Chemicals Inc Acido polihidroxido carboxilico y su procedimiento de obtencion.
US5456679A (en) * 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5209746A (en) * 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
DE69329295T2 (de) * 1992-12-02 2001-03-15 Alkermes Controlled Therapeutics, Inc. Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
US5468253A (en) * 1993-01-21 1995-11-21 Ethicon, Inc. Elastomeric medical device
CA2474701C (fr) 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation de microparticules biodegradables contenant un agent biologiquement actif
US5556905A (en) * 1994-03-30 1996-09-17 Reilly Industries, Inc. Physically-modified degradable thermoplastic compositions
DE69524398T2 (de) * 1994-04-08 2002-07-18 Atrix Laboratories, Inc. Flüssige mittel zur wirkstoffabgabe
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
UA10911C2 (uk) * 1994-08-10 1996-12-25 Мале Впроваджувальне Підприємство "Іhтерфалл" Біосумісhий гідрогель
US5639851A (en) * 1995-10-02 1997-06-17 Ethicon, Inc. High strength, melt processable, lactide-rich, poly(lactide-CO-P-dioxanone) copolymers
US6113624A (en) * 1995-10-02 2000-09-05 Ethicon, Inc. Absorbable elastomeric polymer
WO1998027962A2 (fr) * 1996-12-20 1998-07-02 Alza Corporation Composition de gel injectable a effet retard et son procede de preparation
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
RU2271196C2 (ru) * 1999-06-04 2006-03-10 Элзэ Копэрейшн Имплантируемая композиция (варианты) и способ ее приготовления
JP2004511431A (ja) * 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
WO2002038185A2 (fr) * 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Systeme d'administration injectable a liberation prolongee comprenant du loperamide
WO2002058670A1 (fr) 2001-01-25 2002-08-01 Euroceltique S.A. Anesthesie locale, et procede d'utilisation
ATE427760T1 (de) * 2001-02-23 2009-04-15 Genentech Inc Erodierbare polymere zur injektion
CA2466632C (fr) * 2001-11-14 2014-02-11 Alza Corporation Compositions en depot injectables et utilisations
MXPA04004664A (es) * 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectables.
MXPA04004665A (es) * 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectable y uso de los mismos.
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
TWI353854B (en) 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
BR0313539A (pt) * 2002-07-31 2005-06-21 Alza Corp Composições depósito de polìmero multimodais injetáveis e seus usos
WO2004012703A1 (fr) * 2002-07-31 2004-02-12 Alza Corporation Compositions retard injectables et utilisation de ces compositions
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles

Also Published As

Publication number Publication date
HK1085387A1 (en) 2006-08-25
ECSP056249A (es) 2006-10-17
UY28067A1 (es) 2003-12-31
AR041913A1 (es) 2005-06-01
CL2003002277A1 (es) 2005-05-06
KR20050088288A (ko) 2005-09-05
CA2504608C (fr) 2013-01-08
US20040151753A1 (en) 2004-08-05
AU2003295409B2 (en) 2010-02-11
EP1581181B1 (fr) 2008-12-24
WO2004043432A2 (fr) 2004-05-27
PL377333A1 (pl) 2006-01-23
RU2355385C2 (ru) 2009-05-20
US7368126B2 (en) 2008-05-06
DE60325511D1 (de) 2009-02-05
WO2004043432A3 (fr) 2004-07-08
TW200503774A (en) 2005-02-01
PE20040675A1 (es) 2004-09-25
ATE418323T1 (de) 2009-01-15
JP2006508127A (ja) 2006-03-09
NZ539810A (en) 2008-03-28
ZA200504529B (en) 2006-08-30
NO20052635L (no) 2005-07-20
MY140155A (en) 2009-11-30
ECSP055838A (es) 2005-09-20
CA2504608A1 (fr) 2004-05-27
AU2003295409A1 (en) 2004-06-03
CN1713890A (zh) 2005-12-28
RU2005117164A (ru) 2006-01-20
NO20052635D0 (no) 2005-06-01
EP1581181A2 (fr) 2005-10-05
BR0315304A (pt) 2005-08-16
MXPA05004927A (es) 2005-09-08

Similar Documents

Publication Publication Date Title
MA27523A1 (fr) Formulation retard a liberation controlee
WO2004105737A3 (fr) Compositions pharmaceutiques et procedes pour inhiber les adherences fibreuses au moyen de differents agents
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
MXPA05013003A (es) Composiciones de deposito elastomerico implantables, usos de las mismas y metodo para elaboracion.
CA2370030A1 (fr) Composition de blocage du canal sodique et leur utilisation
GB0108592D0 (en) Therapeutic agents
EP1139753A4 (fr) Preparations destinees au traitement de maladies et procedes s'y rapportant
WO2005034998A3 (fr) Procedes et compositions destines au traitement de la douleur et d'autres etats a mediation adrenergique alpha-2
BR0016828A (pt) Polìmeros superabsorventes
WO2007000778A3 (fr) Compositions pharmaceutiques a liberation modifiee et leurs procedes
BRPI0412557A (pt) forma de dosagem farmacêutica de eventos cardiovasculares
WO2004034975A3 (fr) Procede permettant de modifier le profil de liberation de compositions a liberation lente
ES2185911T3 (es) Composiciones farmaceuticas que contienen polimeros de ortoester tamponados.
ATE357928T1 (de) Pharmazeutische zusammensetzung für thrombinpeptidderivaten
DK1073456T3 (da) Anvendelse af osteoprotegerin til forebyggelse og behandling af kardiovaskulære sygdomme
TW200637618A (en) Compositions and methods for treating conditions of the nail unit
ATE413177T1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
TW200503689A (en) Pharmaceutical compositions of atorvastatin
CL2003002356A1 (es) Compuestos derivados de 1-(1-acetil-piperidin-4-il)-(ester o amida)-4-(bencidrilo sustituido)-2-tert-butil-piperazina, composicion farmaceutica, y su uso en la inhibicion de 17b-hidroxiesteroide deshidrogenasa de tipo 3 y de enfermedades que dependen
WO2007067519A3 (fr) Utilisation de neurotransmetteurs et de neuropeptides pour le traitement de maladies de secheresse oculaire et de conditions associees
TW200503690A (en) Pharmaceutical compositions of atorvastatin
PT1152776E (pt) Composicao de oligomero-polimero injectavel biodegradavel
DK1073436T3 (da) Forbedret fremgangsmåde til udryddelse af helicobacter pylori
EP1680098A4 (fr) Liberation prolongee de molecules actives d'un point de vue pharmacologique positivement chargees a partir d'une matrice contenant des polymeres avec des atomes d'oxygene polarises
IL161600A0 (en) Compounds and method for the treatment of over-active bladder